Updated results from the phase 3 COMBI-v trial of a combination of dabrafenib and trametinib for the first-line treatment of patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma showed that patients are living significantly longer on the combined therapy than patients treated with vemurafenib alone. The median overall survival time in patients with metastatic melanoma with V600 mutations in the BRAF gene who received the combination treatment was 25.6 months, whereas it was 18 months in patients receiving vemurafenib alone.
Presented at the European Cancer Conference (ECC) 2015 by Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France.
